Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

SAP QM–LabWare Interface: Hidden Integration Risks That Delayed Batch Release

In many global pharmaceutical companies, SAP Quality Management and LabWare LIMS should operate as one connected quality system.

SAP creates an inspection lot for a specific material and batch. Next, the interface transfers the inspection information to LabWare. Laboratory analysts then perform the required tests and record the results. Finally, LabWare sends the results and usage-decision information back to SAP so the company can complete the inspection lot and release the batch.

However, a material number, batch version, plant, specification, or inspection-type mismatch can interrupt this process.

As a result, LabWare may fail to post results for only some batches. SAP may display a generic error, analysts may repeat the posting process, and IT teams may restart interface jobs. Meanwhile, Quality Assurance may wait for the Certificate of Analysis or the final usage decision.

Consequently, a relatively small data mismatch can stop batch release.

These failures do not represent only technical IT problems. Instead, they can expose weaknesses in master data governance, interface validation, deviation management, data integrity, and end-to-end process ownership.

Therefore, a structured GAP Assessment must evaluate the complete SAP QM–LabWare environment, including master data, mapping rules, interface controls, validation documentation, error management, reconciliation, and governance.

Our team assessed the SAP QM–LabWare data flow and identified the main interface gaps. We then proposed risk-based actions to improve control, traceability, and inspection readiness.

Challenges Faced

A detailed GAP analysis in Quality Management Systems is essential for identifying process deficiencies effectively.
  • Master Data Mismatches: Different material, batch, plant, unit, or specification data in SAP and LabWare can prevent results from linking to the correct inspection lot.
  • Batch and Site Mapping Errors: Missing batch versions, plant codes, or storage locations may cause posting failures or send results to the wrong lot.
  • Specification Misalignment: Changes to SAP specifications or inspection types may not be reflected in LabWare, disrupting result transfer.
  • Process and Ownership Gaps: Poor coordination, unclear ownership, and premature batch creation can turn recurring interface issues into repeated IT tickets.
  • Uncontrolled Workarounds: Using similar or incorrect material records weakens traceability and increases reconciliation work.
  • Technical and Monitoring Weaknesses: Poor documentation, generic errors, incomplete validation, and ignored interface failures can leave results unposted.
  • Compliance Risk: Repeated failures may affect data integrity, traceability, CAPA, system validation, and compliance with 21 CFR Part 11, 21 CFR 211.68, and EU GMP Annex 11.

Zamann Pharma Support’s Approach

  • Current-State Interface Assessment: Our team reviewed the complete SAP QM–LabWare workflow, from inspection lot creation to result posting and error handling.
  • Centralized Interface Issue Register: We proposed one controlled register for failures, corrective actions, and resolution times. Significant events should also follow the GMP deviation process.
  • Mapping Documentation Review: Our team documented key mappings between SAP, LabWare, and middleware, including materials, batches, plants, specifications, and results.
  • Error Classification: We classified recurring failures by material, batch, plant, specification, middleware, and technical error type.
  • Master Data Onboarding Controls: We proposed a controlled process for SAP creation, LabWare data, interface mapping, testing, and change approval.
  • Batch-Version Mapping Rules: Our team defined consistent rules for batch versions, suffixes, sub-batches, and rework batches across all systems.
  • Interface Validation and Regression Testing: We reviewed validation records and defined risk-based tests for upgrades, transports, mapping changes, and failure handling.
  • Improved Error Transparency: We recommended clear, actionable error messages and practical training for QC and QA teams.
  • Periodic Reconciliation: The company should regularly compare LabWare results with SAP inspection lots, usage decisions, and rejected transactions.
  • Cross-Functional Interface Ownership: We proposed one Interface Owner to coordinate QA, QC, Production, IT, Master Data, and system owners.
  • Integration with the Data Integrity Program: The assessment covered missing results, incomplete transfers, incorrect links, delayed decisions, and manual workarounds.
  • Global Standardization: We recommended consistent batch, material, and specification rules across all plants and laboratories.
  • Performance Monitoring: The company should monitor failures, resolution time, recurring incidents, unposted results, and open reconciliation items.

Results Achieved

  • Consistent Batch-Key Handling: The company standardized batch-version rules across SAP, LabWare, and middleware, with automated testing after format changes.
  • Improved Error Understanding: Clearer messages helped QC and QA identify material, batch, and mapping issues faster.
  • Stronger Master Data Control: A structured onboarding process aligned SAP records, LabWare data, interface mapping, and pre-production testing.
  • Better Interface Visibility: Issue registers and reconciliation reports exposed unposted results and recurring interface failures.
  • Improved Traceability: Consistent mapping strengthened the link between laboratory results, inspection lots, and usage decisions.
  • More Effective Change Control: Risk-based testing linked system and master data changes to formal impact assessment and validation.
  • Clearer Cross-Functional Accountability: The Interface Owner model created end-to-end responsibility across IT, QA, QC, and Production.
  • Greater Inspection Readiness: The remediation improved validation, data transfer control, deviation management, CAPA, and reconciliation.
  • Reduced Batch-Release Disruption: Better control of data, mappings, and posting errors reduced delays in inspection-lot completion and batch release.
Laboratory
GMP qualification and lifecycle validation activities including IQ, OQ, and PQ supporting inspection readiness in pharmaceutical manufacturing.
Services

Qualification and Validation for GMP Systems

Our team supports the planning, execution, and maintenance of qualification and validation activities, including IQ, OQ, and PQ, to keep GMP-regulated systems compliant and under control.

Read More

Contact Us

Need help? Don't hesitate to get in touch
Zamann pharma support is committed to protecting and respecting your privacy, and we’ll use your personal information to administer your account and to provide the products and services you requested from us.

FAQ

1. Why does LabWare show “inspection lot not found” for only certain batches?

This error often occurs when SAP expects a different batch key, batch-version suffix, plant, or inspection-lot combination. For example, LabWare may post results for BATCH123, while SAP expects BATCH123-01. The investigation should compare the exact material, batch version, plant, and open inspection-lot data in both systems.

2. Which SAP QM–LabWare interface functions require regression testing after a system change?

The regression test should cover material and batch transfer, plant mapping, specifications, inspection characteristics, result posting, usage decisions, and error handling. Companies should execute this test set after relevant SAP transports, LabWare upgrades, middleware changes, or modifications to batch and material rules.

3. How should a GMP laboratory identify LabWare results that never reached SAP?

The laboratory should run a daily or weekly reconciliation report that compares completed LabWare results with SAP inspection-lot, result-recording, and usage-decision status. The quality system should investigate every unmatched or rejected transaction according to its significance.